Reports

1626 Results (Page 4 of 66)

Rare Diseases Markets Research Reports

Rare Diseases

Spain Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis

Spain Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

India Cystic Fibrosis Drugs Market Analysis

India Cystic Fibrosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Cystic Fibrosis Drugs is expanding as a result of rising incidence and prevalence of cystic fibrosis globally, existance of potential pipeline candidates, methods of early detection and treatment, growing awareness of the potential threat caused by cystic fibrosis and rising use of pharmacological therapy. Vertex Pharmaceuticals, AbbVie, Viatris, Nestl? Health Science, Teva pharmaceuticals are the top key market players operating in the global cystic fibrosis market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Pompe Disease Drugs Market Analysis

Australia Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Cryptococcosis Therapeutics Market Analysis

Egypt Cryptococcosis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of the bacteria most frequently linked to human illness. The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Alport Syndrome Therapeutics Market Analysis

UK during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Glioma Therapeutics Market Analysis

France Glioma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Brain and spinal cord tumours called gliomas attack the glial cells in the brain. Positive regulatory environments and the rising prevalence of gliomas are two variables that are expected to drive market expansion. Having a robust pipeline is anticipated to be a key factor in driving the market for glioma therapeutics during the course of the projected period. Over the course of the projected period, it is anticipated that the prevalence of brain tumours would spur market expansion. Global companies in the Glioma Therapeutics Market are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc, Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Sun Pharmaceutical Industries, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals LLC Ltd., Novartis International AG, Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Optic Neuritis Therapeutics Market Analysis

Spain Optic Neuritis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rising incidence of optic neuritis is anticipated to fuel market expansion on a global scale. The rising prevalence of multiple sclerosis may be a major market driver. The usage of intravenous steroids such as prednisone, prednisolone, and others are anticipated to increase, which will help support market expansion. Major global players in Optic Neuritis Therapeutics Market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

India Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis

India Cystic Fibrosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Duchenne Muscular Dystrophy (DMD) Drugs is expanding as a result of rising incidence and prevalence of duchenne muscular dystrophy, improved diagnosis of the disease, emergence of mutation specific and gene specific therapies, favourable government initiatives and supportive regulatory environments in various countries. Sarepta therapeutics, PTC therapeutics, Santhera pharmaceuticals are the top key market players operating in the Cystic fibrosis drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

Australia Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Cystic Fibrosis (CF) Therapeutics Market Analysis

Egypt Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Anal Fistula Therapeutics Market Analysis

UK During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis

France Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Ovarian Cancer Therapeutics Market Analysis

Spain Ovarian Cancer Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors driving the growth of the ovarian cancer market is the rising prevalence of the disease. Other important drivers are the development of new therapies and treatments, rising healthcare expenses, and increased government support. Due to greater public awareness of healthcare issues, the market for ovarian cancer is also expanding. Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

India Eosinophilic Esophagitis Drugs Market Analysis

India Eosinophilic Esophagitis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for eosinophilic esophagitis drugs is growing rapidly as a result of increase in awareness programs for disorders associated with eosinophils, development and use of new generation of non- invasive diagnostic tools, increase in use of eosinophilic esophagitis drugs and therapies for the treatment of various inflammations by physicians worldwide, increase in research and development activities and clinical trials conducted by pharmaceutical firms, promising eosinophilic esophagitis pipeline. Astra Zeneca, Sanofi, Cipla, Glaxo smith kline ,Arena pharmaceuticals, Takeda pharmaceuticals are the top key market players operating in the global eosinophilic esophagitis drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Pyruvate Kinase (PK) Deficiency Market Analysis

Australia Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Cytomegalovirus Therapeutics Market Analysis

Egypt Cytomegalovirus Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A member of the Herpesviridae family with an envelope, the human herpesvirus 5 (HHV-5) is also referred to as cytomegalovirus. Around 40% to 100% of adults worldwide have experienced HHV-5 exposure at some point in their lifetime, making it a very common virus. A rise in the frequency of cytomegalovirus infection, investments in research & development, and the introduction of novel medicines are some of the reasons driving the growth of the market for cytomegalovirus therapeutics. Several Global pharmaceutical firms, including Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others are active in this Cytomegalovirus Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Angelman Syndrome Therapeutics Market Analysis

UK During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Hemophilia A Therapeutics Market Analysis

France Hemophilia A Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of or failure with regard to clotting factor VIII characterises the rare inherited bleeding condition known as haemophilia A. It is the most prevalent form of haemophilia and primarily affects men, though it can also afflict women who carry the gene mutation. Hemophilia A market development goes beyond traditional markets, with a stronger emphasis on increasing access to care in developing markets. In areas where access to specialised care and therapies may be restricted, efforts are being made to improve diagnosis, treatment infrastructure, and pricing. Some of the notable companies operating in the Hemophilia A therapeutics market include BioMarin Pharmaceutical Inc, Bayer AG, Pfizer Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Shire (now part of Takeda Pharmaceutical Company Limited), CSL Behring LLC, Sanofi S.A., Grifols S.A. and Octapharma AG.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis

Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

India Erythropoietin Drugs Market Analysis

India Erythropoietin Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for erythropoietin drugs is growing rapidly as a result of rising prevalence of chronic diseases like kidney diseases, cancer, HIV globally and requirements of erythropoietin drugs in these diseases, rise in anemia in patients, growing awareness about blood related disorders like anemia, patent expiration of innovator drugs and development of generic drugs, development of erythropoietin biosimilars and therapeutic benefits offered by erythropoietin drugs. Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Celltrion, Inc., and Biocon Limited are the key market players operating in global erythropoietin drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Australia Rare Hematology Disorders Market Analysis

Australia Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Dilated Cardiomyopathy Therapeutics Market Analysis

Egypt Dilated Cardiomyopathy Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The phrase "dilated cardiomyopathy" refers to conditions that affect the heart muscle and is regarded as a deadly cardiac condition. Reduced myocardial contractility and left and right ventricular dilatation are usually its defining characteristics. The potential driving force behind the DCM Therapeutics Market has been the rise in diagnostic alterations and symptom awareness, as well as declining dietary and lifestyle choices that have led to an increase in the occurrence of disease. The government is sponsoring research and development (R&D) projects to encourage scientists and pharmaceutical firms to create novel treatments. Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation, and many others are key players in the market for cystic fibrosis (CF) therapeutics.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Ankylosing Spondylitis Therapeutics Market Analysis

UK Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Hemophilia B Therapeutics Market Analysis

France Hemophilia B Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. The increasing prevalence of haemophilia B, improvements in available treatments, and greater public knowledge of the condition have all contributed to the steady growth of the global market for therapies for the condition. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. Takeda Pharmaceutical Company Limited (previously Shire), Takeda Pharmaceutical Company Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Phenylketonuria Therapeutics Market Analysis

Spain Phenylketonuria Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for phenylketonuria therapeutics is being driven by a variety of factors, including the increasing prevalence of PKU, technological advancements in PKU diagnostics, government initiatives and funding, and growing patient demand for effective treatments for the condition. Major global players in Phenylketonuria Therapeutics Market are DAIICHI SANKYO COMPANY, LIMITED, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., SOM BIOTECH, S.L. Healthcare, Synthetic Biologics, Inc., Nestl?, Codexis, BioMarin, Erytech Pharma.,

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

subscribe to our newsletter
up